Cargando…

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Vakrou, Styliani, Liu, Yamin, Zhu, Li, Greenland, Gabriela V., Simsek, Bahadir, Hebl, Virginia B., Guan, Yufan, Woldemichael, Kirubel, Talbot, Conover C., Aon, Miguel A., Fukunaga, Ryuya, Abraham, M. Roselle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222321/
https://www.ncbi.nlm.nih.gov/pubmed/34162896
http://dx.doi.org/10.1038/s41598-021-89451-6
_version_ 1783711470758920192
author Vakrou, Styliani
Liu, Yamin
Zhu, Li
Greenland, Gabriela V.
Simsek, Bahadir
Hebl, Virginia B.
Guan, Yufan
Woldemichael, Kirubel
Talbot, Conover C.
Aon, Miguel A.
Fukunaga, Ryuya
Abraham, M. Roselle
author_facet Vakrou, Styliani
Liu, Yamin
Zhu, Li
Greenland, Gabriela V.
Simsek, Bahadir
Hebl, Virginia B.
Guan, Yufan
Woldemichael, Kirubel
Talbot, Conover C.
Aon, Miguel A.
Fukunaga, Ryuya
Abraham, M. Roselle
author_sort Vakrou, Styliani
collection PubMed
description Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-obstructive HCM (R403Q-MyHC, R92W-TnT)/littermate-control hearts at 24 weeks of age, and in myectomy tissue of patients with obstructive HCM/control hearts (GSE36961, GSE36946). Additionally, we examined myocyte redox, cardiac mitochondrial DNA copy number (mtDNA-CN), mt-respiration, mt-ROS generation/scavenging and mt-Ca(2+) handling in mice. We identified distinct allele-specific gene expression in mouse-HCM, and marked differences between mouse-HCM and human-HCM. Only two genes (CASQ1, GPT1) were similarly dysregulated in both mutant mice and human-HCM. No signaling pathway or transcription factor was predicted to be similarly dysregulated (by Ingenuity Pathway Analysis) in both mutant mice and human-HCM. Losartan was a predicted therapy only in TnT-mutant mice. KEGG pathway analysis revealed enrichment for several metabolic pathways, but only pyruvate metabolism was enriched in both mutant mice and human-HCM. Both mutant mouse myocytes demonstrated evidence of an oxidized redox environment. Mitochondrial complex I RCR was lower in both mutant mice compared to controls. MyHC-mutant mice had similar mtDNA-CN and mt-Ca(2+) handling, but TnT-mutant mice exhibited lower mtDNA-CN and impaired mt-Ca(2+) handling, compared to littermate-controls. Molecular profiling reveals differences in gene expression, transcriptional regulation, intracellular signaling and mt-number/function in 2 mouse models at established disease stage. Further studies are needed to confirm differences in gene expression between mouse and human-HCM, and to examine whether cardiac phenotype, genotype and/or species differences underlie the divergence in molecular profiles.
format Online
Article
Text
id pubmed-8222321
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82223212021-06-24 Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy Vakrou, Styliani Liu, Yamin Zhu, Li Greenland, Gabriela V. Simsek, Bahadir Hebl, Virginia B. Guan, Yufan Woldemichael, Kirubel Talbot, Conover C. Aon, Miguel A. Fukunaga, Ryuya Abraham, M. Roselle Sci Rep Article Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM). We analyzed the transcriptome in 2 mouse models with non-obstructive HCM (R403Q-MyHC, R92W-TnT)/littermate-control hearts at 24 weeks of age, and in myectomy tissue of patients with obstructive HCM/control hearts (GSE36961, GSE36946). Additionally, we examined myocyte redox, cardiac mitochondrial DNA copy number (mtDNA-CN), mt-respiration, mt-ROS generation/scavenging and mt-Ca(2+) handling in mice. We identified distinct allele-specific gene expression in mouse-HCM, and marked differences between mouse-HCM and human-HCM. Only two genes (CASQ1, GPT1) were similarly dysregulated in both mutant mice and human-HCM. No signaling pathway or transcription factor was predicted to be similarly dysregulated (by Ingenuity Pathway Analysis) in both mutant mice and human-HCM. Losartan was a predicted therapy only in TnT-mutant mice. KEGG pathway analysis revealed enrichment for several metabolic pathways, but only pyruvate metabolism was enriched in both mutant mice and human-HCM. Both mutant mouse myocytes demonstrated evidence of an oxidized redox environment. Mitochondrial complex I RCR was lower in both mutant mice compared to controls. MyHC-mutant mice had similar mtDNA-CN and mt-Ca(2+) handling, but TnT-mutant mice exhibited lower mtDNA-CN and impaired mt-Ca(2+) handling, compared to littermate-controls. Molecular profiling reveals differences in gene expression, transcriptional regulation, intracellular signaling and mt-number/function in 2 mouse models at established disease stage. Further studies are needed to confirm differences in gene expression between mouse and human-HCM, and to examine whether cardiac phenotype, genotype and/or species differences underlie the divergence in molecular profiles. Nature Publishing Group UK 2021-06-23 /pmc/articles/PMC8222321/ /pubmed/34162896 http://dx.doi.org/10.1038/s41598-021-89451-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Vakrou, Styliani
Liu, Yamin
Zhu, Li
Greenland, Gabriela V.
Simsek, Bahadir
Hebl, Virginia B.
Guan, Yufan
Woldemichael, Kirubel
Talbot, Conover C.
Aon, Miguel A.
Fukunaga, Ryuya
Abraham, M. Roselle
Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title_full Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title_fullStr Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title_full_unstemmed Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title_short Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
title_sort differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222321/
https://www.ncbi.nlm.nih.gov/pubmed/34162896
http://dx.doi.org/10.1038/s41598-021-89451-6
work_keys_str_mv AT vakroustyliani differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT liuyamin differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT zhuli differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT greenlandgabrielav differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT simsekbahadir differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT heblvirginiab differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT guanyufan differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT woldemichaelkirubel differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT talbotconoverc differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT aonmiguela differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT fukunagaryuya differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy
AT abrahammroselle differencesinmolecularphenotypeinmouseandhumanhypertrophiccardiomyopathy